Category: left
-
IN8bio shares target left unchanged from Laidlaw on glioblastoma study By Investing.com
•
(NASDAQ:INAB) IN8bio Inc. (NASDAQ:INAB) on Monday received a Buy rating and a $7.50 stock target from Laidlaw, following the latest presentation of clinical study results. Over the weekend, the company updated its Phase 1 study of INB-200 in the treatment of glioblastoma (GBM) at the American Society of Clinical Oncology…
-
Market Expert Says Bitcoin Price Has Officially Left The Danger Zone, Can Price Strike $100,000?
•
Cryptocurrency analyst Rekt Capital It was recently suggested that the worst may be over for Bitcoin. If so, the flagship cryptocurrency could be poised for a move to the upside, rising to AS Up to $100,000which is what some other cryptocurrency analysts expected. Bitcoin is out of the “danger zone”…